Catalyst
Slingshot members are tracking this event:
Paratek (PRTK) Expects Top-Line Data in Q2 for Phase 3 Trial Evaluating Omadacycline in Treatment of Community Acquired Bacterial Pneumonia (CABP)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PRTK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 03, 2017
Occurred Source:
http://investor.paratekpharma.com/phoenix.zhtml?c=253770&p=irol-newsArticle&ID=2259424
Related Projects
- Exploring Paratek's (PRTK) Lead Candidate, Omadacycline, for the Treatment of CABP (community acquired bacterial pneumonia) After the Phase 3 Data Readout PRTK, CEMP Executed On: Jul 21, 2017 at 02:00 PM EDT
Related Keywords
Top-line Data, Phase 3, Omadacycline, Community Acquired Bacterial Pneumonia, Cabp
